Scholar Rock presents SRK-439 preclinical data showing lean mass preservation and initiates Phase 2 EMBRAZE trial

Scholar Rock Holding Corp

Preclinical DIO mouse study: SRK-439 with semaglutide preserved lean mass (26.4g vs 22.3g at 4 weeks, p<0.001) and increased relative lean mass (65.8%) after semaglutide withdrawal vs control (57.1%).
SRK-439 attenuated fat mass rebound after semaglutide withdrawal: relative fat mass 18.0% vs 28.7% (p<0.01) and reduced inguinal and epididymal adipose weights.
First participants dosed in Phase 2 EMBRAZE proof-of-concept trial of apitegromab in obesity patients on GLP-1 RA background therapy to assess lean muscle preservation.
Data presented at ADA 84th Scientific Sessions on June 23, 2024, supporting SRK-439's potential for healthier weight management and long-term metabolic benefits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.